Ionis Pharmaceuticals, Inc. Capital Expenditures Incurred but Not yet Paid
Ionis Pharmaceuticals, Inc. (IONS) reported Capital Expenditures Incurred but Not yet Paid of $478.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-02-26
- Ionis Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2019-12-31 was $0.00.
- Ionis Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2018-12-31 was -$246.00K.
- Ionis Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2017-12-31 was $0.00.
- Ionis Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $478.00K, a 49.52% decline from fiscal 2024.
- Ionis Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $947.00K, a 450.58% increase from fiscal 2023.
- Ionis Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $172.00K.
- Ionis Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2020 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|
| 2025-12-31 | $478.00K 10-K · filed 2026-02-26 | ||
| 2024-12-31 | $947.00K 10-K · filed 2026-02-26 | ||
| 2023-12-31 | $172.00K 10-K · filed 2026-02-26 | ||
| 2020-12-31 | $0.00 10-K · filed 2021-02-24 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $0.00 10-K · filed 2021-02-24 | |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-06 | ||
| 2018-12-31 | -$246.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $3.35M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $3.60M 10-Q · filed 2019-11-06 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 | |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-06 | ||
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |